Allena Pharmaceuticals, Inc.

89 articles about Allena Pharmaceuticals, Inc.

• Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

  7/19/2022

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD).

• Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

  7/12/2022

  Allena Pharmaceuticals, Inc. announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock.

• Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

  5/4/2022

  Allena Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with an investor for the issuance and sale of an aggregate of 1,436.0688 shares of its Series D Convertible Preferred Stock, and 1,436.0688 shares of its Series E Convertible Preferred Stock in a registered direct offering for an aggregate gross proceeds of approximately $2.8 million, before deducting placement agent fees and other offering expenses.

• Allena Pharmaceuticals Provides Clinical and Corporate Update - Jan 04, 2022

  1/4/2022

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, provided a clinical and corporate update.

• Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

  11/15/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will present at the Stifel 2021 Virtual Healthcare Conference.

• Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

  11/10/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), today reported financial results for the third quarter and nine months ended September 30, 2021, and highlighted recent corporate progress.

• Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

  11/3/2021

  Allena Pharmaceuticals, Inc. today announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

• 

  Clinical Catch-Up: September 27-October 1

  10/4/2021

  It was a busy week for clinical trial news. Here’s a look.

• Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

  9/29/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), today reported that it has dosed the first patient in a second Phase 2a trial of ALLN-346 (the ALLN-346 202 Trial), a novel, orally-administered, urate-degrading enzyme in development for the treatment of gout in patients with chronic kidney disease (CKD).

• Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

  9/9/2021

  Allena Pharmaceuticals, Inc. today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th , 2021.

• Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

  8/10/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

• Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

  8/3/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12th Annual Wedbush PacGrow Healthcare Conference

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 03, 2021

  8/3/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of inducement awards to two new employees.

• Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  7/14/2021

  Allena Pharmaceuticals, Inc. announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company’s common stock and warrants to purchase up to an aggregate of 10,678,872 shares of the Company’s common stock, at a purchase price of $1.311 per share of common stock and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.

• Allena Pharmaceuticals Provides Update on Clinical Development Programs

  7/12/2021

  Allena Pharmaceuticals, Inc. provided progress updates on its clinical programs: ALLN-346, a first-in-class, oral urate degrading enzyme in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease and reloxaliase, a first-in-class, oral oxalate degrading enzyme in development for the treatment of patients with enteric hyperoxaluria.

• Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

  7/8/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference.

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021

  7/7/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of inducement awards to two new employees.

• Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney DiseaseWebinar Scheduled for Wednesday, June 16th @ 12 pm EDT

  6/8/2021

  Allena Pharmaceuticals today announced that it will host a key opinion leader (KOL) webinar on Wednesday, June 16, 2021 at 12:00 pm Eastern Daylight Time.

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 08, 2021

  6/8/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of an inducement award to a new employee.

• Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

  5/11/2021

  Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022